A Study of ALS-008176 in Infants Hospitalized With RSV
A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dosing and Multiple Ascending Dosing in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection
Sponsor: Alios Biopharma Inc.
Listed as NCT02202356, this PHASE1 trial focuses on Respiratory Syncytial Virus Infections and remains completed. Sponsored by Alios Biopharma Inc., it has been updated 14 times since 2014, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Mar 2025 — Sep 2025 [monthly]
Completed PHASE1
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
▶ Show 9 earlier versions
-
May 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — May 2019 [monthly]
Completed PHASE1
-
May 2018 — Jun 2018 [monthly]
Completed PHASE1
-
Apr 2018 — May 2018 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Mar 2018 — Apr 2018 [monthly]
Recruiting PHASE1
-
Oct 2017 — Mar 2018 [monthly]
Recruiting PHASE1
-
Jun 2017 — Oct 2017 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Feb 2017 — Jun 2017 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alios Biopharma Inc.
For direct contact, visit the study record on ClinicalTrials.gov .